These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 5035811)

  • 21. Effect of oral administration of calcium carbonate, aluminum hydroxide gel and dihydrotachysterol on renal acidosis.
    Ueda H; Ikeda H; Sasaki Y; Shioji R
    Tohoku J Exp Med; 1978 Jan; 124(1):1-11. PubMed ID: 635890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of a new phosphate binder in chronic renal insufficiency.
    Rutherford E; King S; Perry B; Blondin J; Finley T; Mason N; Sparks R; Slatopolsky E
    Kidney Int; 1980 Apr; 17(4):528-34. PubMed ID: 7392426
    [No Abstract]   [Full Text] [Related]  

  • 23. Hypercalcaemia from calcium resin in patients with chronic renal failure.
    Sevitt LH; Wrong OM
    Lancet; 1968 Nov; 2(7575):950-1. PubMed ID: 4176267
    [No Abstract]   [Full Text] [Related]  

  • 24. The treatment of uremic hyperphosphatemia.
    Schaefer K
    Clin Nephrol; 1996 Oct; 46(4):279-80. PubMed ID: 8905221
    [No Abstract]   [Full Text] [Related]  

  • 25. Oral aluminium hydroxide in the treatment of hyperphosphatemia and acidosis in acute and chronic renal insufficiency.
    LINDHOLM T
    Acta Med Scand; 1962 Jul; 172():75-8. PubMed ID: 14465480
    [No Abstract]   [Full Text] [Related]  

  • 26. [Administration of colloidal aluminium hydroxide to patients under chronic hemodialysis].
    Vokrouhlická O; Erben J; Zahradník J; Dvoráková-Bastecká D
    Cas Lek Cesk; 1977 May; 116(19):594-7. PubMed ID: 880597
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of renal osteopathy].
    Keller F; Schwarz A; Kraft D
    Fortschr Med; 1985 Mar; 103(10):268-70. PubMed ID: 3979935
    [No Abstract]   [Full Text] [Related]  

  • 28. Aluminum-free intestinal phosphate binding.
    Schneider H; Kulbe KD; Weber H; Streicher E
    Contrib Nephrol; 1984; 38():32-6. PubMed ID: 6713898
    [No Abstract]   [Full Text] [Related]  

  • 29. [The natural history of dialysis encephalopathy (author's transl)].
    Pogglitsch H; Wawschinek O; Holzer H; Petek W; Ladurner G; Katschnig H; Korthals C
    Acta Med Austriaca; 1980; 7(3):71-6. PubMed ID: 7223340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypercalcaemia from calcium ion-exchange resin in patients on regular haemodialysis.
    Papadimitriou M; Gingell JC; Chisholm GD
    Lancet; 1968 Nov; 2(7575):948-50. PubMed ID: 4176266
    [No Abstract]   [Full Text] [Related]  

  • 31. Aluminium encephalopathy: a potential risk of aluminium gels in children with chronic renal failure.
    Pillion G; Loirat C; Blum C; Poisson M; Bacri JL; Broyer M; Mathieu H
    Int J Pediatr Nephrol; 1981 Mar; 2(1):29-32. PubMed ID: 7333766
    [No Abstract]   [Full Text] [Related]  

  • 32. [Use of Aloglutamol in uremic patients on dialysis (author's transl].
    Bonanno A; Tonini GM; de Marinis S
    Urol Int; 1978; 33(4):213-21. PubMed ID: 705977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Stercoral peritonitis. Unusual complication of treatment by aluminum gels in patients with renal insufficiency under long-term hemodialysis].
    Salmon R; Aubert P; David R; Guédon J
    Med Chir Dig; 1979; 8(4):329-31. PubMed ID: 502625
    [No Abstract]   [Full Text] [Related]  

  • 34. [Effects of aluminum gels on renal osteodystrophy caused by chronic hemodialysis. Increase in the total surface of osseous resorption in anephric patients].
    Fournier A; Tunchot S; Bedrossians J; Idatte JM; Bordier P
    Sem Hop; 1974 Nov; 50(45):2803-10. PubMed ID: 4375854
    [No Abstract]   [Full Text] [Related]  

  • 35. [Dialysis-encephalopathy].
    Pogglitsch H; Wawschinek O; Holzer H; Petek W; Katschnig H; Korthals C
    Wien Med Wochenschr Suppl; 1980; 64():14-5. PubMed ID: 6933753
    [No Abstract]   [Full Text] [Related]  

  • 36. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors in aluminum toxicity in children with chronic renal failure.
    Santos F; Massie MD; Chan JC
    Nephron; 1986; 42(3):189-95. PubMed ID: 3511396
    [No Abstract]   [Full Text] [Related]  

  • 38. [How far should the serum concentration of inorganic phosphate be lowered in patients with chronic uremia?].
    Eigler J; Grabensee B; Henning HV
    Med Welt; 1982 Jan; 33(4):115-6. PubMed ID: 7062836
    [No Abstract]   [Full Text] [Related]  

  • 39. Calcium carbonate can enhance aluminium absorption from aluminium hydroxide in patients with impaired renal function.
    Lin JL; Leu ML
    Nephrol Dial Transplant; 1996 Sep; 11(9):1891-3. PubMed ID: 8918652
    [No Abstract]   [Full Text] [Related]  

  • 40. Management of hyperphosphataemia in renal dialysis patients.
    Raine AE; Oliver DO
    Lancet; 1987 Mar; 1(8533):633-4. PubMed ID: 2881172
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.